Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
41.34
-0.92 (-2.18%)
Feb 21, 2025, 4:00 PM EST - Market closed
Revolution Medicines Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for Revolution Medicines stock have an average target of 65.15, with a low estimate of 42 and a high estimate of 87. The average target predicts an increase of 57.60% from the current stock price of 41.34.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 8, 2025.
Analyst Ratings
The average analyst rating for Revolution Medicines stock from 13 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 7 | 7 | 7 |
| Buy | 7 | 7 | 7 | 6 | 6 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 13 | 13 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy Maintains $65 → $71 | Strong Buy | Maintains | $65 → $71 | +71.75% | Jan 8, 2025 |
| Wedbush | Wedbush | Buy Maintains $70 → $67 | Buy | Maintains | $70 → $67 | +62.07% | Dec 6, 2024 |
| Needham | Needham | Strong Buy Maintains $68 → $62 | Strong Buy | Maintains | $68 → $62 | +49.98% | Dec 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $64 → $72 | Strong Buy | Maintains | $64 → $72 | +74.17% | Dec 4, 2024 |
| Guggenheim | Guggenheim | Strong Buy Maintains $82 → $87 | Strong Buy | Maintains | $82 → $87 | +110.45% | Dec 3, 2024 |
Financial Forecast
Revenue This Year
306.00K
from 11.58M
Decreased by -97.36%
Revenue Next Year
5.98M
from 306.00K
Increased by 1,855.56%
EPS This Year
-3.54
from -3.86
EPS Next Year
-4.04
from -3.54
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 4.7M | 73.5M | 43.6M | |||
| Avg | 306,000 | 6.0M | 4.7M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -59.2% | 23,919.6% | 628.2% | |||
| Avg | -97.4% | 1,855.6% | -21.8% | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -3.54 | -3.78 | -4.02 | |||
| Avg | -3.54 | -4.04 | -4.31 | |||
| Low | -3.90 | -4.56 | -4.64 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.